Merck receives two positive EU CHMP opinions
FROM THE WIRE · FINANCE.YAHOO.COM
Merck (NYSE:MRK) received positive opinions from the European Medicines Agency's CHMP on new indications for ENFLONSIA and WELIREG. The CHMP backed ENFLONSIA for preventing RSV disease in young children, expanding Merck's pediatric infectious disease reach in Europe. The…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive opinions on new indications for a large drugmaker, relevant to its European portfolio.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The CHMP backed ENFLONSIA for preventing RSV disease in young children.
- 02The CHMP also supported WELIREG combined with lenvatinib for advanced renal cell carcinoma in adults.
- 03The decisions concern Merck's European indications.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets